# A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors

> **NCT05351502** · PHASE1 · RECRUITING · sponsor: **Beyond Air Inc.** · enrollment: 38 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Nitric Oxide 25,000 ppm
- **DRUG:** Nitric Oxide 50,000 ppm
- **DRUG:** Nitric Oxide 100,000 ppm
- **DRUG:** Nitric Oxide selected dose

## Key facts

- **NCT ID:** NCT05351502
- **Lead sponsor:** Beyond Air Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-14
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05351502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05351502, "A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05351502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*